Karla works with eligible patients exploring wellness-focused peptide programs, including GLOW Blend, BPC-157, TB-500, GHK-Cu, Sermorelin, Tesamorelin, Ipamorelin, CJC-1295, KLOW, Wolverine Blend, NAD+ therapy, and physician-guided medical weight loss programs
What the research shows: A phase 2 randomized, double-blind, placebo-controlled trial published in the New England Journal of Medicine (Jastreboff et al., 2023) enrolled 338 adults with obesity
www.parkinson.org/living-with-parkinsons/treatment/exercise
For example, researchers of the OASIS 1 trial evaluated the effect of a 50 mg oral dose of semaglutide
Faler ND Video Transcription Dave: People may not realize how much seed oils and sugar are fueling inflammation every single day in their lives
The Trajectory: Rapid growth